- 19057
Hospital 57357 is participating in the launch of a postgraduate program in pharmacogenetics and personalized medicine (OPPM) in collaboration with Alexandria University and 11 other partners.
in collaboration with Alexandria University, Hospital 57357, participated in the preparation of the postgraduate program in pharmacogenetics and personalized medicine (OPPM), co-funded by the Erasmus+ program in November 2021. The program was launched in 2023.
The program is a collaborative initiative between leading academic institutions, aiming to equip future pharmacists with knowledge in personalized medicine.
The program was developed in collaboration with Egyptian and Arab institutions, such as: Nile University, Fayoum University, Al-Alfi Foundation, the Magdi Yacoub Foundation, the Egyptian Ministry of Communications, the American University of Beirut, the Arab University in Beirut, in addition to foreign partners: Newcastle University in England, Kiel University in Germany, Oviedo University in Spain, and Democritus University of Thrace in Greece.
It is a pioneering program in developing the blended learning approach in Egypt and Lebanon, characterized by combining traditional teaching methods with information technology and virtual electronic laboratories, through which laboratory experiments can be conducted online, to provide a comprehensive learning management system.
The program also provides practical training in the Personalized Medication Management Unit at the Children’s Cancer Hospital Egypt, 57357.
This collaboration with Hospital 57357 is due to the existence of the Personalized Medication Management Unit in the hospital, which is the first and only unit of its kind in Egypt and the Arab world in the field of pharmacogenetics and personalized medicine.
The program’s curriculum includes:
Online Pharmacogenomics and Personalized Medicine (OPPM) – Postgraduate Program.
617303-EPP-1-2020-1-EG-EPPKA2-CBHE-JP.
The Education, Audiovisual and Culture Executive Agency (EACEA).
Submitted to the call
Erasmus+ KA2 (Capacity Building in Higher Education).
With the receiving of International Accreditation of Hospital and Health System Pharmacy Services (ASHP), the pharmacy department of CCHE 57357 is listed on the ASHP website among the renowned hospitals known for their quality pharmaceutical services.
Strenuous collaborative efforts of various departments of the hospital over the past year were finally crowned with ranking CCHE 57357 as the world’s first hospital of its kind (charitable pediatric oncology hospital) to achieve such recognition from the ASHP. The ASHP is an American organization that ensures through its accreditation system, a hospital’s compliance to medication safety and effectiveness standards and procedures, and the delivery of high-quality pharmaceutical care, consequently improving healthcare outcomes. Previously, thanks to ECN Egypt Cancer Network‘s support, 57357 pharmacy obtained the ASHP accreditation of its residency program made available to its pharmacists. The ASHP international pharmacy residency program accreditation has ensured the availability of the needed facilities as well as the exemplary learning environment offered by CCHE 57357’s pharmacy to its pharmacists, making them a role model in the clinical pharmacy field.
Since the start of operation of CCHE 57357’s pharmacy, administration was keen on providing the appropriate training for each pharmacist according to each pharmacy unit requirements. Dr Sarah Mohamed, 57357’s pharmacy manager, stresses the role and contribution of continuous staff development in the present quality of pharmaceutical services offered to our patients , services that fulfilled the ASHP accreditation standards and requirements.
Moreover, pursuing the automation of the pharmacy, mirrored in the use of the upgraded pyxies machines, the acquisition of Rowa, the robotic dispensing machine, and Diana, the machine used for the IV mix medications unit, have greatly contributed to the special recognition of the CCHE 57357’s pharmacy performance throughout the accreditation process. Also, the existence of a clear administrative and organizational structure for the pharmacy department was one of the factors that contributed to obtaining accreditation and was reflected in the improvement of the quality of patient care, safety, and satisfaction.
Furthermore, medication safety is one of the criteria of the certification which is diligently sought by the 57357-pharmacy team, as they monitor adverse drug reactions, efficacy, and suggest individualization of dosage regimen while also providing patient counseling.
An established safety system is adopted by the pharmacy department and insures the availability of emergency drugs within reach in various areas of the hospital along with the presence of a well-trained emergency pharmacist as a part of the code blue team.
It is worthy to note that obtaining the JCI accreditation since 2016 twice in a row, has paved the way towards the recent achievement of the ASHP accreditation.
We are thrilled to announce that Children’s Cancer Hospital Egypt (CCHE) 57357 has been honored with the prestigious UAE International Genomics Award 2024 as a Health Innovation Trailblazer for its outstanding contributions to pediatric cancer research and personalized medicine. This recognition underscores our commitment to advancing healthcare through cutting-edge genomics and innovative patient care.
The Health Innovation Trailblazer Award is granted to academic individuals, academic institutes, and healthcare industry initiatives with impactful genetic research. CCHE 57357 won the 2024 regional award for the non-profit/ NGO sector.
CCHE received the 2024 Health Innovation Trailblazer Award for pursuing the best possible outcomes for children, commitment to evidence-based medicine, compassionate care, and unwavering dedication. Moreover, the award recognized CCHE for promoting innovation in genetic research that has the potential to drive significant improvement in the quality of life of patients, families, and healthcare providers. As the hospital is advancing solutions with a multifaceted research approach, the award was granted to CCHE on three interconnected fronts;
As the largest pediatric oncology hospital worldwide, CCHE 57357 is committed to being a place of healing and a hub for cutting-edge research, which is one of the organization’s strategic goals.
At CCHE 57357, our commitment to advancing pediatric oncology extends beyond research—it’s about translating breakthroughs into tangible benefits for our young patients. CCHE labs exemplify the intersection of technology, precision, and patient-centric care.
Cutting-edge research meets clinical diagnostics in CCHE 57357 high-tech diagnostic clinical and surgical pathology CAP-accredited labs, where science fuels hope for a healthier future. Our dedication to excellence echoes through every diagnosis and every treatment plan. At CCHE 57357, research isn’t an abstract concept it’s a lifeline for our young warriors.
Clinical Pathology Lab: Unleashing Molecular Insights
The Clinical Pathology Lab at 57357 is a beacon of innovation equipped with cutting-edge technology. Within its walls, molecular and cytogenetic diagnostics take center stage. State-of-the-art equipment enables genetic analysis, including DNA sequencing and chromosomal studies. Moreover, the lab employs Next Generation Sequencing (NGS), a game-changer that swiftly decodes genetic information. The lab paves the way for targeted treatments guided by each patient’s unique genetic profile by identifying mutations and chromosomal abnormalities.
Surgical Pathology Lab: Where Automation Meets Precision
Meanwhile, the surgical pathology lab stands as a model of modernity, where automation meets precision. The entire workflow, from specimen processing to slide preparation, is fully automated, ensuring efficiency and accuracy. Additionally, the lab delves into the molecular intricacies of tumors through molecular and cytogenetic analysis. By understanding genetic markers, they refine diagnoses and tailor treatments, emphasizing
personalized care.
With a profound commitment to excellence and innovation, hand in hand with a keen sense of social responsibility and accountability, CCHE is utilizing these labs to serve and benefit the adult population from our surplus services production of the automated labs at a preferential cost. These unique lab services are offered to the adult population at a convenient price and the highest quality, contributing to the treatment journey of children with cancer.
At CCHE 57357, we strongly emphasize personalized care for pediatric patients dealing with hereditary diseases. Our dedicated team of physicians and scientists operates the genetic counseling clinic, offering essential support and education to families navigating the complexities of these conditions. By doing so, we directly enhance patients’ lives and empower them to make informed decisions about their health.
Furthermore, CCHE 57357, in collaboration with Egypt Cancer Network 57357 (ECN USA), has made a strategic investment in the education of the genetic counseling clinic team. Earlier this year, the first accomplished graduate from Northwestern University in Chicago (one of the world’s leading genetic counseling programs) is back and oversees the genetic counseling clinic and a dedicated team of physicians and scientists. CCHE’s unwavering commitment to expanding this service locally and globally holds immense potential to impact countless families facing positively
these genetic challenges.
3. Basic Research Unit
In 2015, the hospital leadership decided to incorporate a fundamental research unit to delve into cancer-related questions, unraveling the intricate biology of the disease. Aiming to bridge the gap between theory and practice, the basic research unit initiative was the second foundation following the footsteps of the clinical research unit that was supported by an excellent digital data-driven approach with a focus on optimizing clinical data processes, monitoring protocols, conducting trials, and analyzing epidemiological data.
Focusing on genomic research, CCHE 57357 is running a Genomics and Epigenomics Research Program, an in-house laboratory boasting state-of-the-art equipment, including high-throughput technologies for genetic research and diagnostics. From whole genome sequencing to non-invasive prenatal testing (NIPT), our dedicated team works tirelessly to unravel genetic mysteries and improve patient outcomes.
CCHE 57357 launched several translational research initiatives and projects, exploring population genetic and epigenetic factors in acute myeloid leukemia, choroid plexus tumors, pineal pure germinomas, Duchenne Muscular Dystrophy, and spinal muscular atrophy. Our commitment to understanding the genetic basis of diseases drives progress.
The basic research unit runs seven specialized programs with researchers striving to uncover novel insights by working independently or collaborating on interdisciplinary projects. Active programs are imaging-based system biology, regenerative medicine, tumor biology, genomics and epigenomics, proteomics and metabolomics, microbiology and immunology, and clinical epidemiology.
Moreover, CCHE, launched in 2012, has a developed biorepository bank, a treasure trove of human biological specimens—tissues, blood, and body fluids—alongside meticulously annotated data awaiting future scientific exploration. This resource ensures that breakthroughs continue to emerge from the heart of CCHE 57357 and will enable researchers to delve deeper into the genetic factors of cancer, paving the way for discoveries and therapies.
CCHE 57357 is currently introducing the “Future Scientist Club”, which is an innovative program designed to inspire and nurture young minds with a passion for science and research. We aim to cultivate a new generation of researchers who will sustain our mission and contribute to the global scientific community. Through hands-on experiences and mentorship, we invest in the bright minds leading tomorrow’s scientific breakthroughs.
We sincerely thank H.E. Sheikh Nahyan Mabarak Al Nahyan, Dr. Maryam bin Matar, and the UAE Genetic Diseases Association for recognizing our efforts. Together, we continue to make significant strides in the fight against childhood cancer, paving the way for a healthier future.
The labs accreditation committee of the College of American Pathologists, CAP, granted Hospital 57357-Egypt the CAP accreditation. The CAP accreditation was obtained after a chain of long examinations and procedures on site which are part of the accreditation program followed by the CAP.
The accreditation covered the following labs at Hospital 57357
Dr. Sherif Abouel Naga, 57357 Group CEO, revealed that pursuing the CAP accreditation for 57357’s labs goes beyond the mere obtaining of a certification; it is a reflection of our commitment to continuous performance improvement. Dr. Sonya Soliman, head of Hospital 57357’s clinical pathology department, shares “we are proud for having obtained the recent accreditation of our labs in nine specializations after the CAP accreditation committee’s first check on site”. The CAP accreditation was obtained after a chain of long examinations and procedures to ensure that Hospital 57357’s labs qualify for more than 3000 standards. It was found to be complying to more than 99% of the standards, which is an impressive achievement (as the CAP team leader announced at the end of the inspection day).
This achievement is another evidence of our commitment since day one to maintaining high quality performance. It affirms our team’s continuous efforts and dedication. Their commitment to highest standards of accuracy and quality has earned them this deserved accreditation. As head of the clinical pathology lab, I believe that this certification is an evidence of our constant pursuit of providing quality services and care to our patients through accurate and precise diagnosis and ultimately improving cure rates. This accreditation is to remind us with our commitment towards patients and families who have entrusted us with their care. It reassures them that they are receiving the highest level of lab services which upholds accurate diagnosis and enhances survival rates .
We are grateful for the great support we receive from the Hospital’s administration and from all hospital departments, we pledge to constantly pursue performance improvement and the provision of best possible quality care and services to our patients who are in dire need of them.”
The USA’s federal government recognizes the CAP’s accreditation program, which came into operation in the sixties of last century and which is committed to the rigorous governmental inspection standards.
During the CAP accreditation, inspectors audit the lab’s records and quality assurance parameters followed by the lab, to guaranty that the lab patients receive the highest care standards. CAP inspectors also review the lab specialists’ qualifications, equipment, facilities, safety programs and the management style in general.
About the CAP:
The College of American Pathologist, CAP, is the largest world organization for pathologists who obtained the board certificate; It is a leading authority in labs accreditation and quality assurance testing program. It serves patient, pathologists and the general public through encouraging and supporting excellence in the field of practicing pathology and lab medicine around the world. For more information please read CAP’s annual report on cap.org.
The Hospital met the accreditation standards with a 100% compliance rate.
We are committed to offering free of charge medical care to our children since day one
The General Authority for Healthcare Accreditation and Regulation GAHAR headed by Dr. Ahmed Taha, announced today, January 10th , 2024, in an official statement that CCHE 57357 obtained the GAHAR certification which lasts 3 years for compliance with the standards of the Authority which is in turn accredited by the International Society for Quality in Health care ISQua
The Hospital gained the accreditation on first try with a compliance rate of 100%
The head of GAHAR praised the Hospital’s quality team efforts to disseminate the culture of quality among employees on different levels, while affirming that obtaining GAHAR is an evidence that Hospital 57357 is committed to offering high quality medical care.
Dr. Taha clarified that the setting up of these standards was done through strict methodological stages according to the best international practices established by the experts of technical committees and the general authority for developing standards that are constantly reviewed and evaluated to be accredited by the ISQua.
It is noteworthy that the Authority’s accreditation standards, which the Hospital qualify for with a compliance rate of 100%, include 274 ones divided into two major parts: patient’s standards which ensure that healthcare is designed according to patient’s satisfaction, needs and personal values, and the Authority’s standards which are designed to establish safe, effective and innovative care within a healthy environment while giving priority to patient safety standards, through committing to the following requirements:
The Hospital’s obtainment of this accreditation is an evidence to our commitment to standard operational procedures and guidelines that we apply from day one, which are established to ensure quality healthcare provided to children with utmost justice, passion and compassion, along with evidence-based planning in every step, as we are working to raise survival rates and committed to achieve our mission with dedication whatever the circumstances are with the vision of a cancer- free childhood.
Through its health performance program arm, the Saudi Kingdom’s Ministry of Health granted the Children’s Cancer Hospital Foundation, CCHF 57357, an award for its remarkable efforts in serving the health system in Egypt and the Arab world. The awarding ceremony took place yesterday February 5th, 2023 in attendance of ambassador Ahmed Farouk, Egypt’s ambassador to Saudi Arabia and his deputy, Minister plenipotentiary Deyaa Hamad.
The award was received by Dr. Amr Ezzat Salama, chairman of the board of trusties of the CCHF 57357 and Egypt’s former minister of high education, on behalf of Dr. Sherif Abouel Naga, the 57357 group CEO and the Hospital’s general manager, whose health condition prevented him from attending the ceremony.
In a recorded video for the occasion, Dr. Abouel Naga expressed his regrets for being unable to attend the ceremony because of his health condition and said; “Hospital 57357 opened in 2007 with 180 beds; with time, the number of beds increased to 386 beds in 2020. Hence, Hospital 57357 became the largest children’s cancer hospital in the world in terms of capacity. Since its inception and until the end of 2020, the Hospital served 94955 patients, with an over-all survival rate of 71.7%. Through applying latest treatment protocols and using up to date technology, we hope to reach the world survival rate of 83%. The number of patients coming to the Hospital to complete their treatment exceeded 18000 annually , where the Hospital is admitting more than 3000 new cases annually”
Dr. Abouel Naga concluded saying: “Every child in the Hospital is considered like our own son; Egypt and Saudi Arabia have been and will always be supportive to each other”.
The Joint Commission International, JCI granted the Children’s Cancer Hospital 57357 the healthcare quality accreditation for the third time after going through the Hospital’s compliance with all the required standards.
The JCI team who came to the Hospital were pleased with the cooperative spirit and professionalism of the Hospital staff. They thanked the entire hospital team for the medical and psychological quality care they provide to their patients as well as their concern to ensure a safe, secure and humane environment for patients and families. They praised the commitment of the hospital to continuous training and development of all levels of staff.
In attendance of the JCI delegation, the Hospital’s CEO, management and a large crowd of employees, 57357 celebrated the third renewal of the JCI accreditation. JCI accredits hospitals around the world for the quality of medical services, safety measurements, infection control and the application of the latest world standards in education, development, technology, research and others, all of which the Hospital successively met for the third time as it received its first accreditation in 2016. The JCI accreditation renewal process is carried out every three years. the JCI delegation went through the compliance of the Hospital with quality standards in medical and non-medical fields such as applying latest treatment protocols, safety measures, infection control, latest international standards in education, development, technology, research, patients’ rights, nursing practices, sanitary measures and food safety.
In attendance and sponsorship of his highness sheikh Mohammed ben Rashid al Maktoum, vice president of United Arab Emirates, prime minister and Dubai governor, Dubai club for journalism organized its third session of “pioneers of Arab social networking” to honor those with positive influence in social media channels.
Hospital 57357 was selected to be honored, in the health category, for its recognized effect on social media, its effective contribution in promoting positive interaction and in encouraging creative thinking among youth and the Arab society. In attendance of leaders of Arab social media networks and influential Arab and international figures, Dr. Sherif Abuel Naga, executive manager of 57357 group and general manager of the Hospital, received the award.
The Emirati website “bayan” declared that the Children’s Cancer Hospital 57357 received the award for being one of the most prominent institutions whose campaigns were widely shared on social media and whose team was able to consolidate its position as an institution that can sustain, develop and grow.
Throughout its years of operation, Hospital 57357 exerted much efforts through social media channels to spread its mission and consolidate values of giving and philanthropy among volunteers around the world, initiating change with respect to the free provision of healthcare services to children with cancer. Through positive interaction in social media channels, it could attract millions of followers, positively affecting charity institutions, and enabling the dissemination of scientific knowledge and 57357’s experience in other communities. Moreover, 57357 encourages and adopts charity initiatives by youth in Egypt and other countries to contribute to supporting our children with cancer. It was able to introduce real change on the level of interaction with its followers, earning their trust and highlighting the importance of enhancing free healthcare provision among the public. As a result, millions of the Hospital’s followers participated in our children’s recovery journey and in ensuring the sustainability of the Hospital’s operations and its development and expansion efforts to be able to serve more children with cancer, and becoming one of the leaders of Arab social communication.
Our gratitude to his highness sheikh Mohammed ben Rashid al Mactoum for acknowledging the Hospital.
Bahrain’s deputy prime minister and chairman of the board of trusties of Isa award for service to humanity, his highness sheikh Mohammed Ben Mubarak Al Khalifa, announces that the Children’s Cancer Hospital Foundation Egypt wins Isa award in its third edition 2015-2017.
Hospital 5357 is proud to announce the receipt of the Joint Commission International (JCI) accreditation on Jan. 20, 2016. The JCI is one of the world’s prominent nonprofit accreditation organizations working to ensure safety and highest quality of care for the patient
